{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:01:47Z","timestamp":1787508107503,"version":"build-2736575974"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background\/objective<\/jats:title>\n                    <jats:p>Efgartigimod, a human immunoglobulin G1 (IgG1) antibody Fc fragment, reduces IgG levels through neonatal Fc receptor (FcRn) blockade. Preliminary observational data suggest that efgartigimod does not impair vaccine-induced T cell\u2013dependent antibody responses. The objective of this study was to further evaluate the effect of efgartigimod on T cell\u2013independent humoral immune response to immunization with a 23-valent polysaccharide pneumococcal vaccine (PPSV23).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this Phase 1 open-label study, healthy adults (N=37) were randomized 1:1:1 into 3 cohorts: EFG-1 (n=12), EFG-2 (n=12), and placebo (n=13). Four weekly efgartigimod (10 mg\/kg intravenously) or placebo infusions were administered with a 6-week follow-up. PPSV23 was administered immediately before (EFG-1\/placebo) or 2 weeks after (EFG-2) the last efgartigimod or placebo infusion. The primary endpoint was change in pneumococcal capsular polysaccharide titers after PPSV23 vaccination. Additional endpoints included opsonizing antibody titers, antigen-specific B cell responses, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Although variability in antibody response was observed for individual participants and serotypes, an increase in IgG levels was observed for all 23 pneumococcal serotypes after vaccination, irrespective of efgartigimod timing. Normal response to vaccination (\u22652-fold increase and &amp;gt;1.3 mg\/L for \u226570% of serotypes) was observed in 90.0% (9 of 10) of the EFG-1 group, 54.5% (6 of 11) of the EFG-2 group, and 33.3% (4 of 12) of the placebo group. Efgartigimod did not impair production of opsonizing antibodies or antigen-specific plasma B cells. No serious\/severe adverse events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results of this exploratory study suggest that efgartigimod has no apparent effect on T cell\u2013independent humoral immune responses to PPSV23 vaccine in healthy adults. Participants in all groups were able to mount antigen-specific IgG responses to vaccination, even when vaccination occurred at the time of maximal reduction in total IgG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT05163834<\/jats:ext-link>\n                      , identifier NCT05163834.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1799480","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T14:00:25Z","timestamp":1778162425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Antoine E.","family":"Azar","sequence":"first","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Johns Hopkins University","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Sleasman","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Duke University School of Medicine","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Steeland","sequence":"additional","affiliation":[{"name":"argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fien M.","family":"Verhamme","sequence":"additional","affiliation":[{"name":"argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0318-6","article-title":"The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases","volume":"67","author":"Sesarman","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.26226\/morressier.56e174ddd462b8028d88aef1","article-title":"Autmmune diseases in low and middle income countries: a neglected issue in global health","volume":"18","author":"Vento","year":"2016","journal-title":"Isr Med Assoc J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.12691\/ijcd-3-4-8","article-title":"The world incidence and prevalence of autoimmune diseases is increasing","volume":"3","author":"Lerner","year":"2015","journal-title":"Int J Celiac Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103326","article-title":"Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019","volume":"22","author":"Cao","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Updated assessment of the prevalence, spectrum and case definition of autoimmune disease","volume":"11","author":"Hayter","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jaci.2022.05.023","article-title":"Comprehensive overview of autoantibody isotype and subclass distribution","volume":"150","author":"Volkov","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/nyas.13561","article-title":"IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders","volume":"1413","author":"Huijbers","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.673339","article-title":"Antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management","volume":"12","author":"Sechi","year":"2021","journal-title":"Front Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and Malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010099","article-title":"Association between immunosuppressive therapy utilized in the treatment of autoimmune disease or transplant and cancer progression","volume":"11","author":"Reyes","year":"2022","journal-title":"Biomedicines"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14961","article-title":"Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample","volume":"32","author":"Ren","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B14","article-title":"Chapter 7 - Infections in systemic autoimmune diseases","volume-title":"Handbook of systemic autoimmune diseases","author":"Dixon-Zegeye","year":"2020"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14153","article-title":"Serious infections in patients with myasthenia gravis: population-based cohort study","volume":"27","author":"Kassardjian","year":"2020","journal-title":"Eur J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14730","article-title":"Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: a Swedish nationwide register study","volume":"28","author":"Verwijst","year":"2021","journal-title":"Eur J Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11091446","article-title":"Vaccination in the era of immunosuppression","volume":"11","author":"Alnaimat","year":"2023","journal-title":"Vaccines"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep"},{"key":"B22","unstructured":"Vaccine recommendations and guidelines of the ACIP: altered immunocompetence\n          \n          \n          \n          2024"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1086\/587063","article-title":"Vaccination in patients with chronic rheumatic or autoimmune diseases","volume":"46","author":"Gl\u00fcck","year":"2008","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7326\/M21-1757","article-title":"Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study","volume":"174","author":"Deepak","year":"2021","journal-title":"Ann Intern Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2022.2104261","article-title":"Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis","volume":"55","author":"Guptill","year":"2022","journal-title":"Autoimmunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting FcRn to generate antibody-based therapeutics","volume":"39","author":"Ward","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892534","article-title":"Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders","volume":"13","author":"Ward","year":"2022","journal-title":"Front Immunol"},{"key":"B35","article-title":"Response to coronavirus 2019 vaccination in patients receiving efgartigimod (phase: poster)","author":"Howard","year":"2022"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/1547691X.2025.2459934","article-title":"Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys","volume":"22","author":"Binazon","year":"2025","journal-title":"J Immunotoxicol"},{"key":"B37","unstructured":"VYVGART full prescribing information\n          \n          \n          \n          2025"},{"key":"B38","unstructured":"VYVGART HYTRULO full prescribing information\n          \n          \n          \n          2025"},{"key":"B39","unstructured":"VYVGART product monograph\n          \n          \n          \n          2023"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2136167","article-title":"Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective","volume":"18","author":"Suzuki","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B42","unstructured":"argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia\n          \n          \n          \n          2024"},{"key":"B43","unstructured":"argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy\n          \n          \n          \n          2024"},{"key":"B44","unstructured":"A study of the safety and effectiveness of efgartigimod in patients with primary sj\u00f6gren's syndrome (pSS) (rho)\n          \n          \n          \n          2024"},{"key":"B45","unstructured":"A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease (UplighTED)\n          \n          \n          \n          2024"},{"key":"B46","article-title":"COVID-19 vaccination response in participants receiving efgartigimod IV or efgartigimod PH20 SC in ADAPT+ or ADAPT-SC+ (phase: poster)","author":"Steeland","year":"2024"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2470542","article-title":"Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models","volume":"21","author":"Warang","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B48","unstructured":"PNEUMOVAX 23 full prescribing information\n          \n          \n          \n          2024"},{"key":"B49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5863\/1551-6776-21.1.27","article-title":"A review of pneumococcal Vaccines: current polysaccharide vaccine recommendations and future protein antigens","volume":"21","author":"Daniels","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020297","article-title":"Response to vaccines in patients with immune-mediated inflammatory diseases: a narrative review","volume":"10","author":"Garcill\u00e1n","year":"2022","journal-title":"Vaccines"},{"key":"B51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41541-024-00902-3","article-title":"T cell independent antibody responses with class switch and memory using peptides anchored on liposomes","volume":"9","author":"Hj\u00e1lmsd\u00f3ttir","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1296665","article-title":"Multiplexed suspension array immunoassays for detection of antibodies to pneumococcal polysaccharide and conjugate vaccines","volume":"13","author":"Dunbar","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00735-14","article-title":"Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function","volume":"22","author":"Daly","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.09.036","article-title":"Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children","volume":"118","author":"Kamchaisatian","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-013-0601-1","article-title":"Pneumococcal vaccine and opsonic pneumococcal antibody","volume":"19","author":"Song","year":"2013","journal-title":"J Infect Chemother"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00112-06","article-title":"Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies","volume":"13","author":"Burton","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"B59","unstructured":"IGG-2 tina-quant igG gen.2 method sheet\n          \n          \n          \n          2024"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/s0091-6749(96)70244-0","article-title":"Anti-pneumococcal antibody response in normal subjects: a meta-analysis","volume":"98","author":"Go","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.07.013","article-title":"Sex differences in antibody responses to the 23-valent pneumococcal polysaccharide vaccination","volume":"127","author":"Chiarella","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1086\/520200","article-title":"Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity","volume":"29","author":"Romero-Steiner","year":"1999","journal-title":"Clin Infect Dis"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2025.2497840","article-title":"Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases","volume":"21","author":"Gwathmey","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1409480","article-title":"Efgartigimod-associated Kaposi's varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review","volume":"15","author":"Ge","year":"2024","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/im9.0000000000000183","article-title":"Varicella-zoster virus reactivation during efgartigimod therapy for generalized myasthenia gravis: A report of two cases","volume":"7","author":"Li","year":"2025","journal-title":"Infect Microbes Dis"},{"key":"B68","unstructured":"VYVGART summary of product characteristics\n          \n          \n          \n          2024"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Front Neurol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102744","article-title":"Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients\u2019 subgroups","volume":"125","author":"Ferri","year":"2021","journal-title":"J Autoimmun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1799480\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T14:00:43Z","timestamp":1778162443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1799480\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2026.1799480"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1799480","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"article-number":"1799480"}}